LUNG CANCER (NSCLC)

This study tests a new drug combination (tunlametinib plus other drugs) in 55 adults with advanced non-small cell lung cancer that has a KRAS mutation and has not responded to prior treatments. The main goal is to see how many patients' tumors shrink or disappear. The study also …

This early-phase trial tests whether adding capivasertib to osimertinib can help people with a specific type of advanced lung cancer (EGFR-mutant NSCLC) that has stopped responding to first-line osimertinib. About 53 adults with certain genetic changes (PIK3CA/AKT1/PTEN) will rec…

This study tests a new drug, ivonescimab, alone or with chemotherapy, in 46 people with advanced non-small cell lung cancer that has specific gene changes and has not responded to prior treatments. The goal is to see if the drug can shrink tumors or slow cancer growth. Participan…

This study tests whether giving the immunotherapy drug cemiplimab before and after surgery can help people with stage II-IIIA non-small cell lung cancer that has high PD-L1 levels. About 33 adults will receive 3 doses of cemiplimab before surgery, then 10 more doses after. The ma…

This study tests a new medicine, PF-08634404, given alone or with chemotherapy for adults with early or locally advanced non-small cell lung cancer. The goal is to see if it helps shrink tumors before surgery or prevents cancer from returning after treatment. About 120 participan…

This study tests whether combining the drug furmonertinib with chest radiation can help control EGFR-positive lung adenocarcinoma that has spread to the lining of the lung, causing fluid buildup. About 63 adults will receive the treatment, and researchers will track how long the …

This study tests a new treatment plan for people with a certain type of lung cancer (KRAS G12C mutation) that can be removed with surgery. Before and after surgery, patients will receive a combination of targeted therapy (glesorasib), immunotherapy (ivonescimab), and chemotherapy…

This study compares two treatments—minimally invasive surgery and targeted radiation—for people with early-stage lung cancer who are considered high-risk. About 182 participants will be randomly assigned to one of the two treatments. The goal is to see which approach better preve…

This study tests a new cell therapy called SL-28 for people with advanced solid tumors that have not responded to standard treatments. The therapy uses donor immune cells to attack the cancer. The goal is to see if it is safe and can shrink tumors in up to 60 participants with va…

This study tests a special PET scan that uses a radioactive probe to detect PD-L1, a protein on tumor cells, in people with lung cancer, melanoma, or other solid tumors. The goal is to see if this scan can predict who will benefit from immunotherapy. About 40 adults aged 18-75 wh…

This early-stage trial tests injecting the chemotherapy drug cisplatin directly into lung tumors using a thin tube with a camera. The goal is to see if this approach is safe and causes fewer side effects than standard IV chemotherapy. The study involves 12 adults with stage IV no…

This study aims to find the best way to measure if a supervised exercise program helps people whose advanced lung cancer is stable on treatment. About 63 participants will join a 3-month rehab program. Researchers will check if it improves their strength, ability to stand up from…

This study will track 300 people with advanced lung cancer whose first immunotherapy treatment stopped working. Researchers will observe which second-line treatments doctors choose and how well they work, including survival time and side effects. The goal is to use real-world dat…

This study tests whether combining 4D MRI scans with standard 4DCT can better track lung tumors and nearby organs as patients breathe during radiation therapy. About 44 adults with stage II-III non-small cell lung cancer will have an MRI before treatment and X-ray videos during t…

This study looks at immune cells in the spit (sputum) and blood of 50 people with advanced lung cancer who are starting immunotherapy. The goal is to find patterns that show who will benefit from treatment and who might have side effects. Researchers hope this will lead to better…

This study aims to see which treatment—lobectomy, segmentectomy, or a newer ablation technique—best preserves lung function in people with early-stage lung cancer. Researchers will use machine learning to combine 3D CT scans and breathing tests to predict recovery over two years.…

This study will review medical records of 600 Chinese patients with advanced non-small cell lung cancer (NSCLC) that has a specific genetic change called KRAS G12C. All patients received the drug IBI351 between August 2024 and August 2025. Researchers will measure how many patien…

This study will use a special PET scan to track a drug called trastuzumab in the bodies of 20 people with advanced lung cancer that has changes in the HER2 protein. The goal is to see if the drug builds up differently in tumors with a HER2 mutation compared to those with too much…

This study looks back at data from 1,000 lung cancer patients with EGFR mutations who received targeted therapy after surgery. Researchers will use artificial intelligence to analyze CT scans, tissue samples, and genetic reports to build a model that predicts treatment success. T…